PRNewsWire
26 Mar 2026, 13:00 UTC · 25w ago
Verdict
Headline leans bearish. We score RGNX −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA placed a clinical hold on REGENXBIO's RGX-111 gene therapy program after a CNS tumor was discovered in a trial participant.
More negative than 99% of claims this week
A securities class action lawsuit alleges REGENXBIO misled investors by claiming no drug-related serious adverse events while concealing safety risks.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
More negative than 91% of claims this week
REGENXBIO shares experienced a 17.8% price decline in a single session on January 28, 2026, following the FDA hold announcement.
More negative than 79% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company faces a securities class action lawsuit following an FDA clinical hold and reports of a CNS tumor in a trial participant.
More negative than 85% of ticker scores this week
The company is mentioned as the subject of a shareholder alert regarding a securities class action lawsuit.
More negative than 85% of ticker scores this week
The company is mentioned in the context of a pending securities class action lawsuit.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
3h ago
−11.3%
Price agrees with the score
$7.50 vs $8.46 close before publication (Mar 25) · not market-adjusted
RGNX chart →
